ArticleCase reports in hematology2025
A Rare Manifestation of CNS Leukemia: A Case Report.
Article in Case reports in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Rare Manifestation of CNS Leukemia: A Case Report.Case reports in hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central nervous system (CNS) involvement in acute myeloid leukemia (AML) is uncommon, reported in < 3% of patients, and confers poor prognosis. We present a 71-year-old Korean woman with prior myeloid sarcoma who progressed to AML and later developed isolated CNS leukemia. Her course included pancytopenia, extramedullary skin lesions, hyperleukocytosis, transfusion-dependent anemia, and elevated LDH. Neurologic decline revealed dural lesions on imaging; cerebrospinal fluid flow cytometry confirmed CNS disease despite negative cytology. She responded to intrathecal methotrexate and high-dose cytarabine, underscoring the need for CNS-directed therapy. Myeloid sarcoma precedes AML in 2%-8% of cases, yet CNS relapse remains rare. Diagnostic challenges arise from nonspecific neuroimaging and overlap with infectious or inflammatory etiologies, highlighting the role of flow cytometry and molecular studies. Median survival after CNS relapse is reported at 3-6 months. This case also illustrates how language barriers may delay diagnosis and complicate management, emphasizing the need for accessible care frameworks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.